Rapid screening value of RSV antigen detection kit (colloidal gold method) in pediatric respiratory tract infections

Significance of Rapid Diagnosis for Pediatric Respiratory Tract Infections

Respiratory syncytial virus (RSV) is one of the most common pathogens causing lower respiratory tract infections in infants and young children, and is particularly prone to outbreaks and epidemics in autumn and winter. For pediatric patients presenting with symptoms such as fever, wheezing, and cough, clinicians need to distinguish RSV infection from other viral or bacterial infections as quickly as possible to guide isolation measures and avoid inappropriate use of antibacterial drugs. The respiratory syncytial virus (RSV) antigen detection kit (colloidal gold method) has become a commonly used tool for rapid screening in outpatient and emergency settings due to its short turnaround time (typically results in 15-20 minutes) and no requirement for specialized equipment.

Detection Principle and Operational Key Points of the Colloidal Gold Method

This kit is based on double-antibody sandwich immunochromatography technology: RSV antigens in the sample bind to specific antibodies labeled with colloidal gold, migrate along the test strip to the test line, and are captured by immobilized antibodies, forming a visible red line. Nasal swabs or nasopharyngeal swabs are generally required for sample collection, and the sample should be immediately placed into the extraction tube for processing after collection. Operators should pay attention to the depth and quality of sample collection to avoid excessive mucus interfering with chromatography. The appearance of the control line indicates that the reagent is valid, and the development of color on the test line indicates a positive result.

Performance in Clinical Application

Multiple evaluations have shown that when sampling is performed in symptomatic infants and young children during the early course of illness (within 3 days), the sensitivity of the respiratory syncytial virus (RSV) antigen detection kit (colloidal gold method) is typically between 70%-85%, with specificity reaching over 95%. Its sensitivity is lower than that of real-time fluorescent PCR but higher than that of viral culture, making it suitable as a first-line screening tool. For pediatric patients with negative results but highly suspicious clinical symptoms, it is recommended to combine with nucleic acid testing or dynamic re-testing. The kit is significantly affected by viral load in the sample, and the risk of false negatives increases in the later course of illness or in asymptomatic carriers. During clinical use, attention should be paid to room-temperature storage conditions (commonly 2-30°C) and shelf life, and expired reagents should be avoided.

Application Scenarios in Primary Healthcare Institutions

Community health service centers or township health centers often do not have PCR testing capabilities, whereas the RSV antigen rapid detection kit (colloidal gold method) can help primary care physicians make rapid preliminary judgments. For pediatric patients who screen positive, isolation and symptomatic supportive treatment can be promptly implemented, and parents can be informed of precautions; for those who are negative but have persistent symptoms, other pathogen infections should be considered and timely referral should be made. Rational application of this kit helps reduce nosocomial cross-transmission and optimize the allocation of medical resources.

Complementary Relationship with Nucleic Acid Testing

It should be clearly understood that the colloidal gold method, as an antigen detection method, cannot replace nucleic acid testing for confirmation or epidemiological investigation. Nucleic acid amplification technology has higher sensitivity and can detect asymptomatic infections or low viral loads. However, during peak disease periods, when outpatient and emergency department volumes are high, the timeliness advantage of rapid antigen detection is evident. Medical institutions can establish a workflow: use antigen detection for initial screening, and if positive, clinical intervention can proceed; if negative or confirmation is needed, then send for PCR.